---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005063"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:47:35.212500+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics reports Q4 revenue $44.4M; ends Janssen deal, cuts workforce to ~220

## Summary
- Cash and investments $441.2M plus $38.5M receivables; total ~$475M as of Dec 31, 2022.
- Q4 2022 revenue $44.4M from collaborations; R&D expense $87.2M, G&A $21.6M.
- Janssen collaboration terminated effective Apr 3, 2023; all programs discontinued.
- Restructuring reduces headcount to ~220; expects $12-16M severance charges in Q1 2023.
- IND planned mid-2023 for FT522 in B-cell lymphoma; FT825/ONO-8250 IND expected in 2023.

## SEC filing metadata
- accession: 0000950170-23-005063
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017023005063/0000950170-23-005063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017023005063/fate-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005063
- JSON: https://secwatch.observer/filing/0000950170-23-005063.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005063.txt

## Key facts
- Earnings Releases
  FATE THERAPEUTICS INC reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On February 28, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017023005063/0000950170-23-005063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.